A common inquiry we receive from patients is what to do if their insurance company has denied their claim related to their cancer treatments. One service we often direct individuals to is the OmbudService for Life and Health Insurance (OLHI). But who are they? And how can they help you?

Over the last few years CBCN has been working to educate patients, physicians and the broader cancer advocacy community about biosimilar therapies.  From our curated digital magazine on biosimilars to our recently released white paper Breast Cancer & Biosimilars: Recommendations on Use, Implementation and Patient Communications-CBCN is committed to raising awareness about the use of biosimilar therapies for treating breast cancer.

Did you know that accessing treatments for stage IV metastatic breast cancer (mBC) is not universal across Canada? We live in a country that promotes universal health care to all but accessing cancer treatment varies by each province.

Tell us a little bit about yourself, where you’re from, and your experience with breast cancer.

Now that you’ve learned more about biosimilars, it may also be of interest to learn what the physician perspective is. We connected with Dr. Sandeep Sehdev, a medical oncologist at the Ottawa Hospital, to get his perspective on biosimilars and what he thinks is important for patients to understand about them.

Biosimilar drugs will soon be entering the breast cancer treatment landscape and are already available for support medications. With these emerging treatment options, it’s important to know more about them so you can make informed decisions about your treatment plan.